Advertisement
Full length article| Volume 265, P96-101, October 2021

Download started.

Ok

Effects of atosiban on uterine peristalsis following frozen embryo transfer: A randomized controlled trial

      Abstract

      Objectives

      To compare the effects of atosiban (oxytocin antagonist) on uterine peristalsis and pregnancy outcomes in the frozen embryo transfer (FET) cycle.

      Setting

      Srinagarind Hospital, a university hospital, Khon Kaen, Thailand.

      Design

      A randomized, double-blinded, controlled trial.

      Methods

      Fifty infertile women were randomized into the atosiban (n = 25) and placebo group (n = 25). Women in the study group received intravenous atosiban 6.75 mg, 30 min before embryo transfer, and continued infusion at 18 mg/h for 1 h. The dose was reduced to 6 mg/h for another 2 h. Saline solution was applied in the placebo group. The uterine peristalsis frequency was measured by transvaginal ultrasound 30 min before and 3 h after the embryo transfer.

      Results

      The respective mean baseline uterine peristalsis frequency (time) in the atosiban and placebo group was 10.3 ± 2.4 and 9.2 ± 3.4. The respective duration of uterine peristalsis in the atosiban and placebo group after receiving the intervention was reduced to 7.9 ± 2.1 and 6.9 ± 2.7. The implantation rate and clinical pregnancy rate were not statistically significant different between atosiban group and placebo group (37.5% versus 31.0%, RR 1.21, 95%CI: 0.60–2.44 and 44% versus 36%, RR 1.22, 95%CI: 0.62–2.42, respectively). Subgroup analysis indicated that the clinical pregnancy rate in those >35 years of age was not significantly different between both groups (31.6% and 18.8 %, RR 1.68, 95%CI: 0.50–5.68).

      Conclusion

      Adding atosiban in FET did not reduce uterine peristalsis but may benefit the advanced age group.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      References

        • Ferraretti A.P.
        • Goossens V.
        • Kupka M.
        • Bhattacharya S.
        • de Mouzon J.
        • Castilla J.A.
        • et al.
        European IVF-monitoring (EIM); Consortium, for The European Society of Human Reproduction and Embryology (ESHRE). Assisted reproductive technology in Europe, 2009: results generated from European registers by ESHRE.
        Hum Reprod. 2013; 28: 2318-2331
      1. CDC. Assisted Reproductive Technology National Summary Report. 2018. <http://wwwcdcgov/art/reports>; 2016.

        • Decleer W.
        • Osmanagaoglu K.
        • Devroey P.
        The role of oxytocin. antagonists in repeated implantation-failure.
        Facts Views Vis Obgyn. 2012; 4: 227-229
        • Richter O.N.
        • Kubler K.
        • Schmolling J.
        • Kupka M.
        • Reinsberg J.
        • Ulrich U.
        • et al.
        Oxytocin receptor gene expression of estrogen-stimulated human myometrium in extracorporeally perfused non-pregnant uteri.
        Mol Hum Reprod. 2004; 10: 339-346
        • Liedman R.
        • Hansson S.R.
        • Howe D.
        • Igidbashian S.
        • McLeod A.
        • Russell R.J.
        • et al.
        Reproductive hormones in plasma over the menstrual cycle in primary dysmenorrhea compared with healthy subjects.
        Gynecol Endocrinol. 2008; 24: 508-513
        • Fanchin R.
        • Righini C.
        • Olivennes F.
        • Taylor S.
        • de Ziegler D.
        • Frydman R.
        Uterine contractions at the time of embryo transfer alter pregnancy rates after in-vitro fertilization.
        Hum Reprod. 1998; 13: 1968-1974
        • Zhu L.
        • Li Y.
        • Xu A.
        Influence of controlled ovarian hyperstimulation on uterine peristalsis in infertile women.
        Hum Reprod. 2012; 27: 2684-2689
        • Tsirigotis M.
        • Pelekanos M.
        • Gregorakis S.
        • Pistofidis G.
        Ritodrine use during the peri-implantation period reduces uterine contractility and improves implantation and pregnancy rates post- IVF.
        Hum Reprod. 2000; 24: 10
        • Bernabeu R.
        • Roca M.
        • Torres A.
        • Ten J.
        Indomethacin effect on implantation rates in oocyte recipients.
        Hum Reprod. 2006; 21: 364-369
        • Kalmantis K.
        • Loutradis D.
        • Lymperopoulos E.
        • Beretsos P.
        • Bletsa R.
        • Antsaklis A.
        Three Dimensional Power Doppler evaluation of human endometrium after administration of oxytocine receptor antagonist (OTRa) in an IVF program.
        Arch Gynecol Obstet. 2012; 285: 265-270
        • Benedetto M.T.
        • De Cicco F.
        • Rossiello F.
        • Nicosia A.L.
        • Lupi G.
        • Dell'Acqua S.
        Oxytocin receptor in human fetal membranes at term and during labor.
        J Steriod Biochem. 1990; 35: 205-208
        • Bossmar T.
        traetment of preterm labor with the oxytocin and vasopressin antagonist Atosiban.
        J Perinat Med. 1988; 26: 458-465
        • Fukai H.
        • Den K.
        • Sakamato H.
        • Kodaira H.
        • Uchida F.
        • Takagi S.
        Study of oxytocin receptor: II. Oxytocin and prostaglandins F2 alplha receptor in human myometrium and amniondecidua complex during pregnancy and labor.
        Endocrinol Jpn. 1984; 31: 565-570
        • Lopez Bemai A.
        • Phipps S.L.
        • Rosevear S.K.
        • Tumbull A.C.
        Mechanism of action of the oxytocin antagonist.
        Br J Obstet Gynaecol. 1989; 96: 1108-1110
        • Meli P.
        Oxytocin antagonists in preterm labor and delivery.
        Baillieres Clin Obstet Gynaecol. 1993; 7: 734-741
        • Moore J.J.
        • Dubyak G.R.
        • Moore R.M.
        • Vander K.D.
        Oxytocin activates the inositol-phospoholipid protein kinase-C system and stimulates prostaglandins production in human amnion cell.
        Endocrinology. 1988; 123: 1771-1777
        • Akerlund M.
        • Stromberg P.
        • Hauksson A.
        • Andersen L.F.
        • Lyndrup J.
        • Trojnor J.
        • et al.
        Inhibition of uterine contractions of premature labour with an oxytocin analoque.
        Br J Obstet Gynaecol. 1987; 94: 1040-1044
        • Goodwin T.M.
        • Paul R.
        • Silver H.
        • Spellacy W.
        • Parsons M.
        • Chez R.
        • et al.
        The effect of the oxytocin antagonist atosiban on preterm uterine activity in human.
        Am J Ocstet Gynaecol. 1994; 170: 474-478
        • Pierzynski P.
        • Gajda B.
        • Smorag Z.
        • Rasmussen A.D.
        • Kuczynski W.
        Effect of atosiban on rabbit embryo development and human sperm motility.
        Fertil Steril. 2007; 87: 1147-1152
        • Moraloglu O.
        • Tonguc E.
        • Var T.
        • Zeyrek T.
        • Batioglu S.
        Treatment with oxytocin antagonists before embryo transfer may increase implantation rates after IVF.
        Reprod Biomed Online. 2010; 21: 338-343
        • Silver H.
        • Valenzuela G.
        • Sanchez-Ramos L.
        • Romero R.
        • Sibai B.
        • Goodwin T.
        • et al.
        Maternal side effect and safety of oxytocin receptor antagonist atosiban.
        Am J Ocstet Gynaecol. 1997; 176: 45
        • Valenzuela G.J.
        • Craig J.
        • Bernhardt M.D.
        • Holland M.L.
        placental passage of the oxytocin antagonist atosiban.
        Am J Ocstet Gynaecol. 1995; 172: 1304-1306
        • Shubert P.J.
        Atosiban.
        Clin Obstet Gynecol. 1995; 38: 722-724
        • Kuijsters N.P.M.
        • Methorst W.G.
        • Kortenhorst M.S.Q.
        • Rabotti C.
        • Mischi M.
        • Schoot B.C.
        Uterine peristalsis and fertility: current knowledge and future perspectives: a review and meta-analysis.
        RBM Online. 2017; 35: 50-71
        • Alpha Scientists in Reproductive Medicine
        • ESHRE Special Interest Group Embryology
        Istanbul consensus workshop on embryo assessment: proceedings of an expert meeting.
        Reprod BioMed Online. 2011; 22: 632-646
        • Zhu L.
        • Che H.S.
        • Xiao L.
        • Li Y.P.
        Uterine peristalsis before embryo transfer affects the chance of clinical pregnancy in fresh and frozen-thawed embryo transfer cycles.
        Hum Reprod. 2014; 29: 1238-1243
        • Lan V.T.N.
        • Khang V.N.
        • Nhu G.H.
        • Tuong H.M.
        Atosiban improves implantation and pregnancy rates in patients with repeated implantation failure.
        Reprod Biomed Online. 2012; 25: 254-260
        • Mueller A.
        • Siemer J.
        • Schreiner S.
        • Koesztner H.
        • Hoffmann I.
        • Binder H.
        • et al.
        Role of estrogen and progesterone in the regulation of uterine peristalsis: results from perfused non-pregnant swine uteri.
        Hum Reprod. 2006; 21: 1863-1868
        • Ng E.
        • Li R.
        • Chen L.
        • Lan V.
        • Tuong H.
        • Quan S.
        A randomized double-blinded comparison of atosiban in patients undergoing IVF treatment.
        Hum Reprod. 2014; 29: 2687-2694
      2. G. Griesinger C. Blockeel P. Pierzynski Tournaye H. Višňová A. Humberstone et al. Effect of the oxytocin receptor antagonist nolasiban on pregnancy rates in women undergoing embryo transfer following IVF: analysis of three randomised clinical trials. Hum Reprod 2021; 1-14.

        • Chou P.Y.
        • Wu M.H.
        • Pan H.A.
        • Hung K.H.
        • Chang F.M.
        Use of an oxytocin antagonist in in vitro fertilization-embryo transfer for women with repeated implantation failure: a retrospective study.
        Taiwan J Obstet Gynecol. 2011; 50: 136-140
        • Kim S.H.
        • Pohl O.
        • Chollet A.
        • Gotteland J.P.
        • Fairhurst A.D.
        • Bennett P.R.
        • et al.
        Differential effects of oxytocin receptor antagonists.
        Mol Pharmacol. 2017; 91: 403-415